Poland· PL-100037684

Lincocin

A lincomycin product containing lincomycinum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 5 of our 19 countries.

ATC J01FF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLincocinATCJ01FF02REGISTER NO.PL-100037684PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Lincomycin is registered in 5 of 19 countries.

Countries holding a registration under ATC J01FF02 (lincomycin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose

Lincomycin · ATC J01FF02

5 / 19 countries

  • Belgiumprice
  • Italyprice
  • Japan
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Lincomycinum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
J01FF02
ATC class
Lincomycin
Defined daily dose
1.8 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990146512

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

31 interactions on record for lincomycin.

Graded by severity as the source publishes them — 11 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lincomycin · interactions on record

31 records

  • 11 moderate
  • 20 info

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • KaolinA07BC02moderate
  • AttapulgiteA07BC04moderate
  • BalsalazideA07EC04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lincomycin in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lincomycin products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Belgium · Lincocin
  • Bulgaria · Линкомицин Абр
  • Cyprus · Comycin, Lincomed
  • Spain · Lincocin
  • Greece · Pecasolin
  • Italy · Lincocin
  • Lithuania · Lincocin
  • Luxembourg · Lincocin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aee982c6-bbcb-4bd5-9d94-03dcf416f81f
GET /v1/drugs/aee982c6-bbcb-4bd5-9d94-03dcf416f81f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909990146512 ¦ Rp ¦ 5805\n12 kaps.",
  "substance": "Lincomycinum 500 mg",
  "common_name": "Lincomycinum",
  "pl_product_id": "100037684",
  "pozwolenie_nr": "01465",
  "auth_procedure": "NAR",
  "authorisation_validity": "2026-05-28"
}

See everything about lincomycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.